Phosphatase and tensin homolog (PTEN) is a phosphoinositide lipid phosphatase and one of the most frequently disrupted tumor suppressors in many forms of cancer, with even small reductions in the expression levels of PTEN promoting cancer development. Although the post-translational ubiquitination of PTEN can control its stability, activity, and localization, a detailed understanding of how PTEN ubiquitination integrates with other cellular regulatory processes and may be dysregulated in cancer has been hampered by a poor understanding of the significance of ubiquitination at individual sites. The function of the phosphatase and tensin homolog (PTEN) 3 tumor suppressor is disrupted in many forms of cancer by diverse mechanisms (1, 2). PTEN is a phosphatidylinositol 3,4,5-trisphosphate lipid phosphatase that acts to oppose the class I phosphoinositide 3-kinases and therefore loss of PTEN function leads to aberrant accumulation of phosphatidylinositol 3,4,5-trisphosphate and activation of downstream oncogenic PI3K-dependent signaling as well as potentially other PI3K-independent changes (2, 3). PTEN is currently known to exist in two forms, a 403-amino acid cytosolic and nuclear protein usually simply called PTEN, and a longer 576-amino acid protein, PTEN-L, which due to its ability to cross cell membranes and inhibit tumor formation when injected into in mice, has been proposed as a protein therapy (4 -6).
The function of the phosphatase and tensin homolog (PTEN) 3 tumor suppressor is disrupted in many forms of cancer by diverse mechanisms (1, 2) . PTEN is a phosphatidylinositol 3,4,5-trisphosphate lipid phosphatase that acts to oppose the class I phosphoinositide 3-kinases and therefore loss of PTEN function leads to aberrant accumulation of phosphatidylinositol 3,4,5-trisphosphate and activation of downstream oncogenic PI3K-dependent signaling as well as potentially other PI3K-independent changes (2, 3) . PTEN is currently known to exist in two forms, a 403-amino acid cytosolic and nuclear protein usually simply called PTEN, and a longer 576-amino acid protein, PTEN-L, which due to its ability to cross cell membranes and inhibit tumor formation when injected into in mice, has been proposed as a protein therapy (4 -6) .
Although in clinical data from some tumor types, notably breast cancer, reduced PTEN mRNA levels correlate well with reduced PTEN protein (7) , in others including prostate cancer, reduced PTEN protein levels are frequently observed in tumors apparently retaining normal levels of PTEN mRNA (8) . Among the mechanisms potentially responsible for this selective loss of PTEN protein expression, accelerated degradation by posttranslational ubiquitination seems likely to contribute. This conclusion is supported by the paradigm established for the p53 protein and the ubiquitin E3 ligase MDM2 that destabilization of tumor suppressor proteins can be a significant oncogenic driver and also accumulating evidence for the dysregulation of ubiquitin ligases and proteases that control PTEN stability in several cancer types (9 -12) .
In addition to its stability, the activity and localization of PTEN can also be controlled by its ubiquitination, notably with PTEN monoubiquitination being linked to its nuclear accumulation (13) (14) (15) . Several E3 ubiquitin ligases have been proposed to contribute to PTEN ubiquitination, including NEDD4 and the related HECT-domain E3 ligase WWP2, as well as XIAP, CHIP, RFP, SPOP, and MKRN1 (9, 10, 16 -20) and ubiquitin proteases have been identified that can deubiquitinate PTEN, including HAUSP/USP7, OTUD3, and USP13 (11, 12, 21) . Although many of these studies have identified important effects of manipulating these ligases and proteases on PTEN function and often PTEN stability, clear pictures are yet to emerge of the molecular details of these regulatory events, in particular the sites at which PTEN becomes ubiquitinated, the form of the ubiquitin chains generated and beyond proteasomal degradation, the mechanisms by which ubiquitination influences PTEN function, such as ubiquitin-dependent binding partners. To date, only two sites of PTEN ubiquitination have been described, lysine 13 (Lys 13 ) and lysine 289 (Lys 289 ), although evidence supports the existence of several more (15) . Here we show that a novel site of PTEN ubiquitination identified in an unbiased proteomic screen, lysine 66 (Lys 66 ), is polyubiquitinated in cells and dominates in the regulation of PTEN stability.
Results
Ubiquitination site prediction software that successfully predicts PTEN Lys 13 (Fig. 1A) . Therefore, we studied the effects on PTEN function and stability of mutating these sites to similarly charged and sized arginine (Arg) residues that cannot be ubiquitinated.
Wild-type PTEN (PTEN WT) and mutants, K13R, K66R, K80R, and K289R were each expressed transiently and polyclonally using lentiviruses in PTEN null U87MG glioma cells alongside a phosphatase inactive mutant in which the active site nucleophilic cysteine is replaced (PTEN C124S) and a known unstable mutant (PTEN A3, which has 3 C-terminal phosphorylation sites mutated to alanine residues, S380A, T382A, T383A termed A3) as controls. Although levels of PTEN mRNA in each sample were not significantly different (Fig. 1B, lower  panel) , levels of PTEN protein expression were significantly higher for PTEN K66R (Fig. 1, B, upper panel, and C) . No significant changes in PTEN protein expression levels were observed for other ubiquitination site mutants (Fig. 1C) . Transfection experiments with independent plasmid expression vectors gave a similar result, showing elevated protein levels for PTEN K66R (Fig. 1D) . None of these mutations greatly affected PTEN activity as assessed by the ability to suppress cellular phosphorylation of the downstream PI3K/PIP 3 -regulated kinase AKT, except the known phosphatase-dead PTEN C124S control (Fig. 1, B and D) . To judge the consistency of this apparent effect, the experiment was repeated in several other PTEN null cell types: MDA-MB-468 breast cancer, PC3, and LNCaP prostate cancer and a PTEN-null clone of HCT116 colon cancer cells (24) . In all cases, as in U87MG cells, expression of PTEN K66R was higher than wild-type and in most cases noticeably higher than the other mutants analyzed (Fig. 1,  E-H) . To test whether the PTEN K66R mutation and the resultant higher levels of mutant protein cause a greater effect on cell Western blotting of total cell lysates using total and phospho-specific antibodies. GAPDH levels were used as a loading control. A representative blot from at least three independent experiments is shown. Parallel samples from U87MG cells transduced with PTEN WT or mutants were used to analyze the levels of PTEN mRNA by quantitative PCR (B, lower panel). The PTEN transcript levels are expressed relative to GAPDH. y axis represents the average levels of transcript Ϯ S.E. from three experiments each performed in duplicate. No significant difference in the transcript levels was observed between PTEN WT and each PTEN mutant-expressing sample. C, bars representing the relative densitometric values of PTEN expression. The quantitation is derived from three independent experiments and values are mean Ϯ S.E. PTEN K66R was significantly more stable compared with PTEN WT (p value Ͻ 0.001). No significant changes in PTEN levels were observed with mutation of other ubiquitin sites (n.s., non significant). D, PTEN-null U87MG glioblastoma cells were transfected with plasmid expression vectors encoding for PTEN WT, PTEN mutants, or EGFP as a control. Cells were lysed 48 h post-transfection and PTEN expression and AKT phosphorylation were investigated by Western blotting analysis of total cell lysates using total and phospho-specific antibodies. GAPDH levels were used as a loading control. A representative blot from three independent experiments is shown. These plasmid transfection experiments recapitulate the increase in PTEN expression with K66R mutation relative to PTEN WT (p value Ͻ 0.001) as observed with a lentiviral transduction approach. E-H, PTEN-null clone of HCT116 colon cancer cells (E), MDA-MB-468 breast cancer cells (F), PC3 (G), and LNCaP prostate cancer cells (H) were transduced with similar units of lentivirus particles encoding for PTEN WT or the indicated PTEN mutants. Control cells were transduced with viruses encoding EGFP. PTEN expression and AKT phosphorylation were investigated by Western blotting analysis of total cell lysates using total and phosphospecific antibodies. GAPDH levels were used as a loading control. In each case a representative blot from at least three independent experiments is shown. In all cases, as in U87MG cells, expression of PTEN K66R was significantly higher than wild-type (p value Ͻ 0.01).
signaling and proliferation, U87MG cells were transduced with increasing doses of multiple independently prepared viruses encoding PTEN WT or PTEN K66R. PTEN K66R viruses always led to a higher PTEN expression level ( Fig. 2A) and showed a concomitant greater inhibition of downstream cell signaling as seen by greater suppression of the phosphorylation of both AKT and ribosomal protein S6 (Fig. 2, A-C) . PTEN K66R expression also had a greater effect on cell proliferation (Fig. 2E ). The observed effects on both signaling and proliferation appear to mirror the PTEN expression level with no evidence for altered specific activity found (Fig. 2D) , suggesting that the K66R mutation increases PTEN protein expression without strong independent effects on protein function.
To dissect the consequences of ubiquitination at individual sites, a mutant was prepared with all the four lysine residues (Lys 13 , Lys 66 , Lys 80 , and Lys 289 ) mutated to arginine, termed 473 phosphorylation from three independent experiments for PTEN WT and PTEN K66R was plotted against the relative PTEN expression levels with increasing doses of PTEN WT or PTEN K66R lentiviruses. E, PTEN-null U87MG cells were transduced with similar units of lentiviruses encoding EGFP, PTEN WT, or PTEN K66R and the viable cell number was quantified bye 5 days post-transduction using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. x axis shows the mean measured cellular metabolic activity relative to EGFP-transduced cells Ϯ S.E. from three experiments each performed in triplicate. t test: **, p value Ͻ 0.01; *, p value Ͻ 0.05; n.s., non significant. PTEN Kall4R (Fig. 3A) . When its expression in several different cell lines was investigated, this mutation of all the four lysine residues together resulted in similar or only marginally greater PTEN expression than K66R mutation alone in all the cell lines examined (Fig. 3, B-E ), further implying a major role for Lys 66 in regulating PTEN turnover. To test the effects of these mutations directly on protein stability, PTEN null cells expressing the mutants were treated with the protein synthesis inhibitor cycloheximide and the decay of extant protein was observed. PTEN A3 was less stable than the wild-type enzyme, whereas PTEN K13R, K80R, and K289R were all similar to, or modestly more stable than, PTEN WT. In contrast, both PTEN K66R and Kall4R with Lys 66 mutated were significantly more stable (Fig.  3, F and G) .
To test the hypothesis that the observed effects of lysine mutations on PTEN stability were mediated directly through changes in ubiquitination, we applied a previously established assay of cellular ubiquitination using FLAG epitope-tagged ubiquitin (13, 25) . These experiments showed strong ubiquitination of wild-type PTEN, which was dramatically lower (ϳ95%) in PTEN Kall4R (Fig. 4) , suggesting that these four lysines do represent the major sites of ubiquitination incorporation into PTEN, or at least are required for incorporation at other sites. Although PTEN K13R, K80R, and K289R appeared to display somewhat lower ubiquitination than PTEN WT, PTEN K66R had very low levels of ubiquitination, similar to Kall4R (Fig. 4) . These results strongly indicate that Lys 66 specifically is required for the normal levels of PTEN polyubiquitination.
To further test the contributions of individual ubiquitination sites and the potential specific significance of Lys 66 , PTEN expression vectors were made in which one of the four mutated ubiquitination sites in PTEN Kall4R (K13R, K66R, K80R, K289R) was mutated back to lysine, so that each construct expresses PTEN with only one of these lysine residues available for ubiquitination. For brevity of labeling, these constructs are referred to as shown in Fig. 5A as, e.g. K13K, which is K66R,K80R,K289R with only the Lys 13 residue available for , and MDA-MB-468 breast cancer cells (E) were transduced with similar units of lentivirus particles encoding for PTEN WT, the indicated PTEN mutants, or control EGFP. PTEN expression and AKT phosphorylation were investigated by Western blotting analysis of cell lysates using total and phospho-specific antibodies. GAPDH levels were used as a loading control. A representative blot from three independent experiments is shown. F and G, the stability of PTEN ubiquitin-site mutants was determined using protein synthesis inhibitor cycloheximide (CHX). F, PTEN-null U87MG cells transduced with viruses encoding PTEN WT or PTEN mutants were treated with 100 g/ml of CHX for the indicated times, followed by immunoblot analysis with anti-PTEN or anti-GAPDH antibodies. The blots shown are representative of three independent experiments. G, plot showing densitometric analysis of the CHX assay. y axis shows the relative PTEN levels (in percent) after normalizing with GAPDH levels. The quantitation is derived from three independent experiments and values are mean Ϯ S.E. Both PTEN K66R and PTEN Kall4R, with Lys 66 mutation, were significantly more stable compared with PTEN WT (p value Ͻ 0.01).
Controlling PTEN Stability: a Dominant Role for Lys 66 ubiquitination out of these four studied ubiquitination sites. Notably, the higher PTEN expression seen in PTEN Kall4R is reduced to WT PTEN levels if lysine 66 is retained in its wild-type form in the PTEN Kall4R background (i.e. K13R,K80R,K289R-labeled PTEN K66K). In contrast, individually retaining Lys 13 , Lys 80 , or Lys 289 in their wild-type form (mutants PTEN K13K, K80K, and K289K, respectively) had no effect on the PTEN expression, with these mutants still showing similar enhanced PTEN expression as seen with PTEN Kall4R (Fig. 5, B and C) . Direct analysis of PTEN protein stability showed that these effects on expression levels correlated with the observed protein half-life, with PTEN proteins retaining Lys 66 showing significantly lower stability than mutants that include the K66R change (i.e. PTEN Kall4R, K13K, K80K, and K289K) (Fig. 5, D and E) , respectively, show low levels of ubiquitination as seen in PTEN Kall4R (Fig. 5F ). These results provide further compelling evidence for a dominant role of Lys 66 in regulating PTEN expression, stability, and its polyubiquitination. Additionally, experiments using antibodies that recognize polyubiquitin chains with specific linkage topologies suggested that the polyubiquitination occurring on Lys 66 of PTEN may be linked through Lys 48 of ubiquitin (a polyubiquitin chain topology that is commonly involved in proteasomal degradation of target proteins), as a stronger signal was apparent with a Lys 48 linkage-specific ubiquitin antibody with immunopurified PTEN K66K (Fig. 5F ). Further methods would need to be used to provide conclusive evidence of chain topology specific ubiquitination.
Unstable PTEN mutant proteins have been identified encoded in the germ line of patients with diverse pathologies that appear to be linked to the biological activity of these mutant enzymes (26 -29) . Treatment of a subset of unstable PTEN mutants found in PTEN hamartoma tumor syndrome (PHTS) patients with proteasome inhibitors could restore mutant PTEN protein levels (30) highlighting an important role for the ubiquitin proteasome pathway in controlling their stability, irrespective of the mechanism(s) by which the relevant PTEN mutations diminish protein stability. Therefore, we investigated the effects of the K66R mutation on the expression of unstable PTEN mutant proteins identified in patients with tumor and autism-related syndromes. Additional mutation of K66R increased the protein expression level of the unstable PTEN mutant proteins D252G and H118P, which have been identified in patients with autism (29) and also appeared to have a similar but more modest effect on PTEN L108P, an unstable PTEN mutant protein that has been identified in patients with severe tumor phenotypes (29, 30) (Fig. 6, A and B) . In further study of the stabilization of the PTEN D252G disease-associated unstable protein, the Lys 66 ubiquitination site seemed dominant over other ubiquitination sites, as all mutant PTEN proteins containing the K66R mutation showed significant stabilization of the D252G mutant enzyme and other Lys to Arg mutations had little or no effect even when combined (termed the D252G,K66K mutant, with only Lys 66 retained in its wildtype form) (Fig. 6, C and D) . It was also noted that the treatment with proteasome inhibitor MG132 lead to a modest increase in the protein stability of the unstable PTEN D252G mutant. Of note, the same MG132 treatment in the PTEN D252G mutant with the additional K66R mutation does not show any further significant increase in the protein levels (Fig. 6E) . Finally, the PTEN K66R mutant was also found to be resistant to the small but significant NO-mediated proteasomal degradation of PTEN that has been proposed as the mechanism for PTEN inhibition in neurodegeneration (31) (Fig. 6F) . Taken together, these results strongly point to a dominant role of the Lys 66 ubiquitination site in controlling ubiquitin proteasome-mediated degradation of PTEN and thus in regulating regulating PTEN expression, stability, and PTEN polyubiquitination. A, schematic illustrating PTEN mutants generated to assess the contribution of individual ubiquitination sites to expression and stability. B and C, HEK293T cells (B) and PTEN-null U87MG glioblastoma cells (C) were transduced with similar units of lentivirus particles encoding for PTEN WT or PTEN mutants or EGFP. PTEN expression was investigated by Western blotting (WB) analysis, GAPDH levels were used as a loading control. A representative blot from three independent experiments is shown. D and E, the stability of these PTEN mutants was determined using protein synthesis inhibitor cycloheximide (CHX). D, U87MG cells transduced with viruses encoding PTEN WT or PTEN mutants were treated with 100 g/ml of CHX for the indicated times, followed by immunoblot analysis with anti-PTEN or anti-GAPDH antibodies. The blots shown are representative of three independent experiments. E, plot showing densitometric analysis of the CHX assay. y axis shows the relative percentage PTEN levels after normalizing to GAPDH. The quantitation is derived from three independent experiments and values are mean Ϯ S.E. PTEN K66K, with only Lys 66 ubiquitination site available, showed significantly lower stability than PTEN Kall4R (p value Ͻ 0.01). PTEN mutants that included the K66R change (i.e. PTEN Kall4R, K13K, K80K, and K289K) showed more or less similar stability with data points falling on top of each other. F, cellular assay for PTEN ubiquitination. U87MG cells were transfected to express FLAG-ubiquitin (FLAG-Ub) and 6 h later transduced with viruses encoding PTEN WT or the indicated PTEN mutants. Lentiviruses were titrated prior to the experiment to ensure similar levels of PTEN protein is expressed in each sample. 48 h post-transfection, cells were treated with 10 M MG132 for 5 h. Cells were lysed, and PTEN was immunoprecipitated (IP) before Western blotting analysis of these immunoprecipitates with antibodies raised against the FLAG epitope, Lys 48 linkage-specific polyubiquitin, Lys 63 linkage-specific polyubiquitin, and PTEN. A smear of high molecular weight in the FLAG Western blot represents polyubiquitinated PTEN. A stronger signal is observed with a Lys 48 linkage-specific antibody in PTEN K66K mutant that has only the Lys 66 site available for ubiquitination out of the four studied ubiquitination sites. In parallel, total cell lysates were immunoblotted with antibodies raised against the FLAG epitope, PTEN, or GAPDH (F, lower panel).
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PTEN stability. We found that the PTEN K66R mutant could equally well bind to PTEN ubiquitin ligase NEDD4 as PTEN WT (Fig. 6G) .
Discussion
In this study, we present the first studies of a novel PTEN ubiquitination site, lysine 66, and show that its mutation causes a large increase in PTEN stability. Our data show that lysine 66 specifically is required for the normal levels of PTEN polyubiquitination and imply that lysine 66 is the site of much of the polyubiquitination on PTEN, promoting the proteasome-mediated degradation of PTEN. Importantly, we found in multiple cell types that PTEN lysine 66 dominates over other known ubiquitination sites (lysines 13, 80, and 289) in regulating PTEN expression, stability, and PTEN polyubiquitination. Two alternate sites of PTEN ubiquitination, Lys 13 and Lys 289 have been previously identified as major monoubiquitination sites essential for cytoplasmic-nuclear shuttling of PTEN (15) . Our data indicate that they can influence PTEN stability but play weaker roles than Lys 66 . It has been previously observed that PTEN ubiquitination can suppress phosphatase activity (13) . Expression of PTEN K66R did have greater effects than the wild-type enzyme on downstream AKT-mediated signaling, however, this correlates with its higher cellular concentration (Fig. 2) . Along with the location of Lys 66 on the surface of the PTEN phosphatase domain facing away from the active site and membrane-interacting surface, this implies that direct effects of PTEN ubiquitination on phosphatase activity are more likely to be mediated through other sites of ubiquitination. Notably, in the context of unstable mutant PTEN proteins that have been identified in sporadic tumors and germline PTEN mutation carriers, we observed that additional mutation of the Lys 66 ubiquitin site could significantly improve PTEN stability.
The up-regulation of PTEN ubiquitin ligases or down-regulation of PTEN deubiquitinases has been implicated in accelerated PTEN degradation and thereby in driving tumorigenesis and has identified these E3 ligases and deubiquitinases as potential drug targets (9 -12) . Future studies firmly identifying the E3 ligases or deubiquitinases, which specifically modify PTEN Lys 66 would be highly relevant for the development of therapies aiming to indirectly enhance PTEN expression. The potential of PTEN as a protein therapy has been raised by the discovery of a cell-penetrant form of PTEN (PTEN-long or PTEN-L), which can cause regression of tumor xenografts when purified protein is injected into mice (4). Additionally, mutations have been identified that improve the cellular activity of PTEN through increased membrane association and could be used in the context of PTEN-L (32). Particularly because increased membrane association of PTEN also leads to polyubiquitination and destabilization (13) , it seems an appealing strategy to engineer the PTEN-L protein in this way with mutations leading both to enhanced activity and stability.
Experimental Procedures
Cell Culture and Lentivirus Transduction-U87MG glioblastoma, MDA-MB-468 breast cancer, PC3, and LNCaP prostate cancer and HEK293T embryonic kidney cell lines were procured from the European Collection of Animal Cell Cultures (Public Health England, Salisbury, UK) and maintained in the recommended medium supplemented with 10% fetal bovine serum (FBS). PTEN-null clone of HCT116 colon cancer cells were kindly provided by Todd Waldman (Georgetown University) and cultured in McCoy's 5A medium with 10% FBS. Standard cell culture medium, additives, and sera were from Invitrogen. Lentiviral particles were prepared as described previously (33) . Cells were transduced with lentiviruses in medium supplemented with Polybrene (16 g/ml; Sigma). The medium was changed 24 h after transduction, and polyclonal cell populations were processed without selection 48 h after transduction.
Preparation of Whole Cell Extracts, SDS-PAGE, and Western Blotting-Cells were washed twice with ice-cold phosphatebuffered saline and lysed in ice-cold lysis buffer (25 mM TrisHCl, pH 7.4), 150 mM NaCl, 1% Nonidet P-40, 1 mM EGTA, 1 mM EDTA, 5 mM sodium pyrophosphate, 10 mM ␤-glycerophosphate, and 50 mM sodium fluoride) containing 0.1% 2-mercaptoethanol and protease inhibitors (0.2 mM phenylmethylsulfonyl fluoride, 1 mM benzamidine, 10 g/ml of aprotinin, and 10 g/ml of leupeptin). Equal amounts of proteins were separated by SDS-PAGE using precast 4 -12% gradient gels (Invitrogen) and blotted onto polyvinylidene difluoride membranes (Polyscreen, PerkinElmer Life Sciences). Most reagents for electrophoresis and blotting were purchased from Invitrogen, and standard manufacturers' protocols were followed. Mouse anti-PTEN monoclonal antibody (clone A2B1) was purchased from Santa Cruz Biotechnology. Antibodies against phospho-AKT (Ser-473), phospho-AKT (Thr-308), total AKT, phospho-S6K (Thr 389 ), total S6K, phospho-S6 (Ser 240/244 ), total S6, Lys 48 linkage-specific polyubiquitin, Lys 63 linkage-specific polyubiquitin and NEDD4 were obtained from Cell Signaling Technologies. Anti-GAPDH antibody was from Merck Millipore. Anti-FLAG antibody M2 was purchased from Sigma.
In Cell PTEN Ubiquitination Assay-Cellular assays to measure PTEN polyubiquitination were performed as described previously (13, 25) . Briefly, where indicated, cells were transfected with vectors encoding PTEN and FLAG epitope-tagged ubiquitin. Whole cell extracts were prepared using lysis buffer containing fresh protease and phosphatase inhibitors and 40 mM N-ethylmaleimide (Sigma). PTEN was immunoprecipitated from an equal volume of the diluted cell lysates containing 1 mg of soluble protein using monoclonal antibody A2B1 precoupled with protein G-Sepharose beads. The proteins bound to beads were released by boiling in SDS-PAGE sample buffer (Invitrogen) for 10 min. The samples were then resolved by 4 -12% SDS-PAGE, followed by immunoblot analysis using anti-FLAG antibody M2 or mouse monoclonal A2B1 anti-PTEN antibody.
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